Healthcare / BiotechnologyHKSE
$1.95
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-348.9M · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$812M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-99.8%
↓Gross Margin
61.0%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.9%
FCF CAGR
—
FCF margin
-27.7%
FCF / Net income
0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $283.7M · net income $-555.3M · FCF $-78.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $283.7M | $283.7M | $158.2M | $173.9M | $145.7M |
| Net Income | $-555.3M | $-555.3M | $-590.6M | $-768.0M | $-846.1M |
| EBITDA | $-458.9M | $-458.9M | $-488.7M | $-655.7M | $-752.3M |
| EPS | -1.34 | -1.34 | -1.43 | -1.87 | -2.06 |
| Gross Margin | 61.0% | 61.0% | 48.9% | 50.7% | 40.3% |
| Operating Margin | -85.5% | -85.5% | -290.3% | -328.1% | -477.9% |
| Net Margin | -195.8% | -195.8% | -373.3% | -441.7% | -580.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.36 | 0.19 | 0.12 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-78.5M | $-78.5M | $-348.9M | $-413.0M | $-637.3M |
| Returns | |||||
| ROE | -99.8% | -99.8% | -50.5% | -45.6% | -35.9% |
| Valuation | |||||
| P/B | 1.46 | 1.46 | 0.45 | 0.54 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | 79.3% | 79.3% | -9.0% | 19.3% | — |
| EPS Growth | 6.3% | 6.3% | 23.5% | 9.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.43 → -1.34
Residual
+16.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.